Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 166Genitourinary 122Other hematologic neoplasm 50Plasma cell 19Myeloid 8Sarcoma 4Dermatologic 4Tumor-Agnostic 3Thoracic 3Breast 2Other solid neoplasm 1CNS 1

Conditions

Neoplasms 3

Interventions

Paclitaxel 26Carboplatin 25pembrolizumab 22Gemcitabine 22Nivolumab 20Cisplatin 15Bevacizumab 14Docetaxel 13Pemetrexed 12Ipilimumab 12Erlotinib Hydrochloride 12Capecitabine 12Fluorouracil 11Irinotecan 10Afatinib 10eribulin 9BI 6727 9130-nm albumin-bound paclitaxel 9Radiotherapy 8Magnetic Resonance Spectroscopy 8Leucovorin 8Everolimus 8Cyclophosphamide 8Albumin-Bound Paclitaxel 8olaparib 7Oxaliplatin 7lenvatinib 6avelumab 6Trastuzumab 6Cetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Prednisone × Tumor-Agnostic × Clear all
NCT03480646 2025-10-29

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Constellation Pharmaceuticals

Phase 1/2 Completed
175 enrolled 23 charts
Tumor-Agnostic

Neoplasms

NCT01650194 2024-12-10

A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients

Astellas Pharma Inc

Phase 2 Completed
60 enrolled 24 charts
Tumor-Agnostic

Neoplasms

NCT01637402 2020-08-17

A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer

University of California, San Francisco

Phase 2 Completed
41 enrolled 14 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡